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Objectives: Surgical and non-surgical management options with pre-treat-
ment biopsy are available for small renal masses (SRMs). The cost-effectiveness 
of these options is unclear. This study aimed to systematically review the cost-
effectiveness of various management options for SRMs, and evaluate these cost-
effectiveness studies. MethOds: A systematic literature review was conducted 
on five databases from inception to December 31, 2014. Search terms consisted 
of three categories of keywords, e.g., ‘economic evaluation’, ‘renal mass’ and 
‘surgery’. Inclusion criteria were 1) original research, 2) full economic evalu-
ation of management options for SRMs, 3) written in English, and 4) with tar-
geted populations aged ≥ 18 years old. Exclusion criteria were 1) investigation of 
metastases only, and 2) case reports etc. Manual search of relevant bibliographies 
was performed. Eligible studies were evaluated using the Consolidated Health 
Economic Evaluation Reporting Standards (CHEERS). Results: Among the 557 
articles retrieved, 6 were included, all of which were cost-utility analyses and 
used Markov models with a lifetime horizon except for one study that adapted a 
10-year horizon. One to three items on the CHEERS checklist were unfulfilled for 
each study. Three studies were from a societal perspective whereas the others 
were from a payer’s perspective. Health states included no evidence of disease, 
recurrence, metastases and death. Transition probabilities were obtained from 
observational studies. Evaluated strategies were surveillance, ablation, and partial 
and radical nephrectomy with/without pre-treatment biopsy. Two studies deter-
mined that pre-treatment biopsy was dominant while two studies found that 
laparoscopic partial nephrectomy was the optimal strategy. The remaining two 
studies concluded that ablation was preferred. cOnclusiOns: The evidence of 
cost-effectiveness of management options for SRMs is limited. The findings of the 
available studies are inconclusive. Large, prospective, randomized clinical trials 
assessing various competing strategies in the management of SRMs are needed 
to inform better decision-making for physicians and patients.
Urinary/Kidney disorders - Patient-reported outcomes & Patient Preference 
studies
PUK14
self-efficacy, HealtH literacy and adHerence to self-care BeHaviors 
in Kidney transPlant reciPients
Campbell ML1, Beardsley RS2, Shaya FT2, Pradel FG2
1U.S. Food and Drug Administration, Silver Spring, MD, USA, 2University of Maryland School of 
Pharmacy, Baltimore, MD, USA
Objectives: Kidney transplant recipients (KTRs) must manage several self-care 
behaviors. They have to take multiple daily medications, look for signs of acute 
rejection, have frequent blood draws and often manage additional chronic condi-
tions. There is limited understanding of underlying behavioral factors that may 
influence KTRs’ adherence to self-care behaviors. This study aims to explore 
the association between self-efficacy, health literacy and adherence to self-care 
behaviors and to describe variations of self-efficacy based on individual KTRs’ 
characteristics. MethOds: KTRs who were 1 to 5 years post-transplant, over the 
age of 18 at the time of transplants and had a single organ transplant were eligible. 
Four hundred and thirty-five eligible KTRs received a mailed survey inquiring 
about self-efficacy, health literacy, medication adherence, and self-care behav-
iors. Self-efficacy was tested as a mediator or as a moderator of health literacy 
on adherence to self-care behaviors. Linear regression analyzed variations of 
self-efficacy in KTRs. Results: One hundred and eighty-two KTRs completed 
the survey (42% participation rate). Mean age of responders was 59.5 (+/-12.1) 
years; 61.0% were male; and 38.1% were African American. The mean time since 
transplant was 38.0 (+/-18.1) months. African Americans had lower self-efficacy 
compared to other patient groups (β = -0.61, p= 0.03). An increase in functional 
health literacy was associated with an increase in self-efficacy (β = 0.72, p< 0.01). 
Self-efficacy was a partial mediator of functional and communicative health 
literacy on adherence to self-care behaviors (functional: α β = 0.32, CI: 0.11-0.60; 
communicative: α β = 0.37, CI: 0.11-0.71). cOnclusiOns: This study provides 
new insights into the factors influencing KTRs’ adherence to self-care behav-
iors. Clinicians need to monitor patients with low self-efficacy and low health 
literacy. The teach-back method and frequent communication can help increase 
self-efficacy. Use of larger font, photos and visual cues will help patients with 
limited health literacy. These methods may optimize KTRs’ adherence to self-care 
behaviors.
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Objectives: To evaluate and compare the medication adherence rate among the 
patients undergoing maintenance Hemodialysis at different hospital setups in 
India. MethOds: A prospective comparative study was conducted at academic, 
corporate and government hospitals after the approval of protocol by the Ethics 
Committee. The patients on hemodialysis of both gender aged between 18-75 
years were enrolled in the study after obtaining the written informed consent 
from the patients. The validated medication adherence rating scale was used 
to evaluate the adherence among the patients. The medication adherence rate 
was scored from 0–8 with higher scores representing better adherence. ANOVA 
test was used to assess the difference in mean scores in medication adherence 
rating among three hospitals patients with p value less than 0.05 was consid-
ered as statistically significant. Results: A total of 200 patients were recruited 
in the study. Out of 200 patients, 104 from academic hospital, 70 from corpo-
rate hospital and 26 from government hospital. The mean age and vintage of 
hemodialysis of the study population were 51.56 years and 41.75 months. 
study (65, 57 in G1-4 and G5 groups, respectively). The mean±SD age of the patients 
was 52.9±7.8 years. Mean±SD monthly cost of illness for the patients on in G1-4 
stages and G5 stage were INR 7882±945 ($127) and INR 13882±1687 ($224), respec-
tively. The mean±SD monthly COI for the patients on dialysis was INR 32171±950 
($519). Of total expenditure 55.4% were spent directly for treating illness (out of 
pocket expenditure). On average a patient on dialysis had spent 3.9 lakh INR per 
year ($6291). Through analysis of sub-groups of patients, it was found that fund-
ing from employer/ Insurance, dialysis, lower socioeconomic status, lower educa-
tion, comorbidities and rural residential have a major impact on COI in patients of 
chronic kidney disease. cOnclusiOns: Monthly cost of illness for the patients in 
G1-G4 and G5 were INR 7882 ($127) and INR 13882 ($224). The study is in progress.
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Objectives: The Lack of Adherence to Immunosuppressive Treatment (LAIT) has 
been associated with Chronic Humoral Rejection (CHR) and decreased graft survival. 
The objective of the present study was to estimate the direct healthcare costs asso-
ciated with the LAIT in Spanish Kidney Transplant (KT) patients. MethOds: A sys-
tematic literature review and survey of 6 KT experts were carried out to identify the 
relevant healthcare resource use associated with suspected LAIT, suspected kidney 
CHR, confirmed CHR and graft loss. Subsequently two economic models were devel-
oped from a Spanish National Health Service perspective: the first using an incidence 
approach (annual cost associated with LAIT according to the incidence of KT patients 
in the year 2013) and the second using a prevalence approach (total costs associated 
with LAIT due to the number of kidney transplanted patients). A sensitivity analysis 
was also performed. Results: According to the incidence approach, the annual cost 
associated with LAIT in Spain is 12,296,243€ , where 80% is driven by graft loss and 
the patient returning to dialysis. The mean cost per non-adherent patient is 18,121€ . 
According to the prevalence approach, out of 25,600 KT patients in Spain (2013), LAIT 
would occur in 6,785 (26.5%) patients, resulting in 705 graft losses. The estimated 
total costs associated with LAIT adds up to 127,224,726€ consisting of 102,647,488€ 
being related to graft loss and return to dialysis; 13,395,015€ due to confirmed CHR; 
9,742,735€ related to suspected CHR; and 1,439,487€ due to LAIT. cOnclusiOns: 
Considering the total number of KT patients in Spain during 2013, the economic 
burden due to lack of adherence to immunosuppressive treatment exceeds 127 mil-
lion Euros, and this figure does not include societal costs. According to our results 
(incidence approach) and considering data from a previous published study, LAIT 
represents 7.1% of healthcare costs associated with the treatment of KT patients.
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Objectives: Kidney transplantation remains limited by toxicities of calcineurin 
inhibitors (CNIs). Belatacept is a less toxic therapeutic alternative, but its cost lim-
its its use. Whether the reduction of renal post-transplant hospitalization balance 
this higher cost has been addressed in two situations: 1- in first line therapy 2- as a 
second line immunosuppressant for CNIs intolerant patients. MethOds: A Cost-
minimization analysis has been performed for 2 groups of patients: Group 1- 7 
Belatacept-treated patients paired to 21 Tacrolimus-treated patients (1:3) over 5 
years post-transplant. Group 2- 12 patients having received transplantation, one 
year before and after their shift from CNI to Belatacept. The study has been con-
ducted from The French Health Insurance (FHI) perspective. Treatment-associated 
costs (based on FHI and hospital purchasing prices) and hospitalization DRG’s costs 
(collected from PMSI database) were compared by a modified Friedman’s proce-
dure and a Wilcoxon rang test, respectively. Results: In both cohorts, the cost 
of belatacept treatment and administration was more expensive than CNIs treat-
ment, dosage and follow-up but there were fewer unscheduled hospitalizations 
with belatacept: Group 1: 69478US$ vs 14900US$, 11±10 vs 17±15 days Group 2: 
14031US$ vs 3778US$, 22±8 vs 50±50 days Taking into account treatment and hos-
pitalization costs over five years on the first cohort remained significantly higher 
with Belatacept as compared to CNIs: 90324US$ versus 38792US$ whereas the shift 
to Belatacept reduced this amount from 54720US$ to 36667US$ over 1 year, so a 
40% decrease of post-transplant management costs. Heterogeneity of the drug 
response and the low number of patients prevented these differences to be statis-
tically significant but belatacept treated patients cohort are sparse. cOnclusiOns: 
This economic analysis shows that beyond potential therapeutic advantages and 
reduction of unscheduled post-transplant hospitalizations, the place of the drug 
in a therapeutic flow chart must include the cost-minimization approach to allow 
patients best healthcare‘s management nowadays.
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Objectives: The Lack of Adherence to Immunosuppressive Treatment (LAIT) 
has been associated with Chronic Humoral Rejection (CHR) and decreased graft 
survival which can increase Health Resource Utilisation (HRU). Prevalence of 
LAIT has been reported to range between 7.4% and 41.8% of Spanish Kidney 
Transplant (KT) patients and published studies suggest LAIT may cause up to 
20-50% of CHR episodes in Spain. The objective of this study was to estimate the 
resource utilization associated with LAIT in KT patients in Spain. MethOds: 
A systematic literature review was conducted using Medline, PsycINFO and 
BVS to identify Spanish studies published between 2009 and 2013 focusing on 
KT and LAIT. Following the review a questionnaire was developed to explore 
HRU associated with LAIT. Six national experts in KT from Spain completed 
the survey and the data was analyzed using Computer Assisted Qualitative 
Data Analysis (CAQDAS). HRU was estimated independently for suspected 
LAIT, suspected CHR, confirmed CHR and graft loss. Results: Suspected LAIT 
and CHR were associated with additional HRU quantified by additional neph-
rologist visits, heightened immunosuppressive blood-level monitoring, and 
2 measurements of anti-HLA antibodies (Luminex), 1 ultrasound scan and 1 
kidney biopsy. Confirmed CHR was associated with additional HRU such as 
increases in the number of follow-up visits from 1 visit every 4-6 months to 1 
visit every 1-2 months, associated monitoring and testing (bloods, ultrasonog-
raphy, donor-specific antibodies, proteinuria). A proportion of these patients 
are treated with intravenous immunoglobulin, rituximab and plasmapheresis, 
and kidney biopsy to check whether CHR is resolved. Finally, most CHR epi-
sodes, up to 60%, cause graft loss with increased HRU associated with intensive 
patients’ follow-up to prepare the return to dialysis and renal replacement ther-
apy. cOnclusiOns: The lack of adherence to immunosuppressive treatment 
may lead to CHR and graft loss with an associated increase of healthcare resource 
utilization.
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Objectives: To study the utility of SSU rRNA and COWP gene PCR-RFLP for the 
detection of C. parvum, C. hominis, C. meleagridis, and C. andersoni. MethOds: 
845 stool samples from 323 patients in renal transplant (RT) recipients and 50 
healthy controls between January 2006 and August 2011 were examined for 
Cryptosporidium by Modified acid-fast (Kinyoun’s) staining technique. DNA was 
extracted and was subjected to PCR-RFLP for species detection in cases positive for 
Cryptosporidium by microscopy. Results: Cryptosporidium was detected more 
commonly among the RT recipients than healthy controls (23/323, vs. 0/50, respec-
tively; p= 0.005). All the Cryptosporidium positive cases (23/23) were detected using 
the PCR-RFLP of SSU rRNA gene, 15/23 were C. hominis and 8/23 were C. parvum. 
Only 17/23 cases were detected by COWP genes of which 9/17 were C. hominis 
and 8/17 were C. parvum. By comparing the SSU & COWP gene PCR-RFLP with 
microscopy as the gold standard, SSU gene PCR-RFLP proved to be more sensitive 
& specific (100%) than COWP (sensitivity & specificity of COWP PCR-RFLP was 
73.9% and 100% respectively). C. meleagridis and C. andersoni were not detected 
in any case. cOnclusiOns: Cryptosporidiosis is a common cause of diarrhea 
in RT recipients. The most common species was Cryptosporidium hominis. SSU 
rRNA PCR-RFLP is more suitable for identification of Cryptosporidium species 
than COWP.
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Objectives: To prioritize comparative effectiveness research (CER) questions to 
improve home dialysis practice using a multicriteria decision analysis (MCDA) 
framework. MethOds: Candidate CER questions (n= 13) were generated and 
refined in PICO format by an international network of nephrologists (n= 28) 
using a nominal group process. The EVIDEM framework was adapted to include 
11 criteria to assess the value of these research questions to improve prac-
tice from a holistic standpoint, including the impact, context and outcomes of 
the CER question, feasibility of study, economics and implementation of study 
findings. Quality of evidence to be generated was also included as a criterion, 
with consideration of 13 subcriteria outlining the risk of bias and precision. 
First, participants were asked to weight each criterion independently of the 
research questions. Second, for each research question, participants assigned a 
score for each criterion. Average overall values of CER questions were obtained 
by combining weights and scores using a linear model. Results: Participants 
assigned highest importance to the following criteria: Impact on patient sur-
vival and other major clinical outcomes, Unmet needs, and Feasibility of the 
CER question. Value of CER questions varied between 48% and 73% of maximum 
value on the MCDA scale. Highest value estimates (> 70%) were obtained for 
research questions exploring the association between vascular access or dialysis 
selection process and mortality/morbidity. Ranking had excellent face validity 
for all criteria. Results of this ranking process were used to prioritize research 
planning for the international network of nephrologists. cOnclusiOns: 
Holistic MCDA provides a useful tool for comparative effectiveness 
research to ensure prioritization of CER questions with highest benefits 
for improving clinical practice, as illustrated by this application for home 
dialysis.
The medication adherence rate scores of the patients at academic hospital 
(4.35 ± 1.31), corporate hospital (4.38 ± 1.10) and government hospital (4.16 ± 
1.28). cOnclusiOns: The overall mean medication adherence rate score of the 
patients is 4.34 ± 1.23 and there is no significant difference in mean scores among 
hemodialysis centres (p 0.722). The health care professionals need to educate the 
patients about their disease state and importance of adherence to prescribed 
medications.
PUK16
concePtUal fraMeworK in interstitial cystitis / Bladder Pain 
syndroMe
Hawken NA1, DAM C1, Nazir J2, Aballéa S3, Hakimi Z4
1Creativ-Ceutical, Luxembourg, Luxembourg, 2Astellas Pharma EMEA, Chertsey, UK, 3Creativ-
Ceutical, Paris, France, 4Astellas Pharma, Leiden, The Netherlands
Objectives: This study aimed to build a conceptual framework in patients with IC/
PBS which is a chronic debilitating condition characterized by pelvic pain, urinary 
urgency, and urinary frequency. It affects around 0.7-1 million people in the US and 
mostly middle aged women. Diagnostic criteria developed for research are not effi-
cient and missing 60% of all cases. Uncertainty surrounds definition, etiology, diag-
nosis, natural history, true prevalence, and most effective treatment(s). MethOds: 
Literature review results were used to design semi-structured telephone inter-
views to elicit concepts of importance for IC/PBS patients on functioning and life. 
Interviews were held with clinical experts and UK patients until saturation of 
concepts. Transcripts were analyzed thematically. Results: Two clinical experts 
and 30 female patients were interviewed. IC/PBS was defined as a chronic pain 
syndrome that may begin as a pathologic process in the bladder in most (but not 
all) patients. Pain and frequency were reported as the most bothersome symptoms. 
Relationships, activities, energy levels, and psychological impact were reported to 
be the key areas of impact. ‘Not being able to do what I used to’ , ‘worry about toilet 
access’ , ‘impact on work life’ , and ‘impact on family / home life’ were mentioned as 
having the greatest impact. A broad range of treatments was reported with a broad 
range of treatment side effects. The experts’ results contributed the following: pain 
drives frequency and younger people report a heavier burden. cOnclusiOns: The 
conceptual framework of this study contributes to the understanding of IC/PBS. IC/
PBS has a profound and debilitating effect on all aspects of patients’ lives, from 
preventing them to work over participating in family life and traveling to being 
house-bound with greatly impacted change in roles and self-perceptions, lead-
ing to feelings of being ‘not-normal’ causing anxiety, depression and even suicidal 
tendencies.
Urinary/Kidney disorders – Health care Use & Policy studies
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Objectives: The medical management of men with Lower Urinary Tract 
Symptoms often involves agents targeting bladder outlet obstruction (BOO) such 
as α -blockers or 5-α reductase inhibitors (5ARI). However, overactive bladder 
(OAB) symptoms may coexist with BOO. This study aims to describe the base-
line characteristics of men who utilize OAB [mirabegron and antimuscarinics 
(AM)] therapy and sequential and combination use of various urologic medica-
tion classes. MethOds: Data from a US commercial database were analyzed for 
men starting OAB therapy between 10/01/12 and 12/31/13. Men were grouped by 
initiation of mirabegron or AM. A 12-month retrospective analysis was conducted 
with patients defined as naïve or experienced to AM therapy 12-month period 
prior to index. Baseline demographics and comorbid conditions were compared. 
Concomitant BOO medications, in use at baseline, initiated, or discontinued during 
the 90 days pre/post index date of mirabegron or AM, were analyzed. Results: 
More men on mirabegron saw a urologist (75% vs 35%), more likely to have BOO 
diagnosed (66% vs 49%) and use in free combination with α -blockers (26% vs 17%) 
and 5ARI (7% vs 4%) therapy versus AM. Baseline characteristics showed mira-
begron patients were older (64 vs 59) and had a higher Elixhauser comorbidity 
index (4.7 vs 4.0) compared with AM patients. Baseline health resource utiliza-
tion (HRU) was higher among the mirabegron cohort for urodynamic (58% vs 
29%), cystoscopy (25% vs 19%), polypharmacy (10.4 vs. 8.2) and overall outpatient 
visits (11.4 vs 8.5). More mirabegron patients had prior prostate (7.6% vs 5.8%) 
and OAB (3.9% vs 0.7%) surgical therapy 12-months prior to index compared to 
AM patients. cOnclusiOns: Male patients receiving mirabegron showed dis-
tinct baseline characteristics. Patients managed by urologists were often more 
complicated with greater baseline HRU. Additional studies to model the impact 
of patient characteristics on outcomes in those prescribed mirabegron and AMs 
may be helpful.
PUK18
lacK of adHerence to iMMUnosUPPressive treatMent in Kidney 
transPlant Patients: estiMation of associated HealtH resoUrce 
Utilization
Serón D1, Alonso Á2, Gainza J3, Mazuecos A4, González E5, Kanter J6, Callejo D7, Fernández-
Ortiz L8, González E8, Toledo A8, Muduma G9
1Hospital Universitario Vall d’Hebron, Barcelona, Spain, 2Complejo Hospitalario Universitario A 
Coruña, A Coruña, Spain, 3Hospital Universitario Cruces, Vizcaya, Spain, 4Hospital Universitario 
Puerta del Mar, Cádiz, Spain, 5Hospital Universitario 12 de Octubre, Madrid, Spain, 6Hospital 
Universitario Doctor Peset, Valencia, Spain, 7Laser Analytica, Oviedo, Spain, 8Astellas Pharma SA, 
Madrid, Spain, 9Astellas Pharma EMEA, Chertsey, UK
